Clinical outcomes of switching to aflibercept using a pro re nata treatment regimen in patients with neovascular age-related macular degeneration who incompletely responded to ranibizumab.
Saved in:
| Title: | Clinical outcomes of switching to aflibercept using a pro re nata treatment regimen in patients with neovascular age-related macular degeneration who incompletely responded to ranibizumab. |
|---|---|
| Authors: | Elwes F; Royal Infirmary of Edinburgh, Edinburgh, UK., Borooah S; The Princess Alexandra Eye Pavilion, Edinburgh, UK. shyamanga@aol.com.; College of Medicine & Veterinary Medicine, University of Edinburgh, Edinburgh, UK. shyamanga@aol.com., Aspinall P; Health and Environment Group, Heriot Watt University, Edinburgh, UK.; College of Medicine & Veterinary Medicine, University of Edinburgh, Edinburgh, UK., Sim PY; College of Medicine & Veterinary Medicine, University of Edinburgh, Edinburgh, UK., Loo CY; College of Medicine & Veterinary Medicine, University of Edinburgh, Edinburgh, UK., Armbrecht AM; The Princess Alexandra Eye Pavilion, Edinburgh, UK., Dhillon B; The Princess Alexandra Eye Pavilion, Edinburgh, UK.; College of Medicine & Veterinary Medicine, University of Edinburgh, Edinburgh, UK., Cackett P; The Princess Alexandra Eye Pavilion, Edinburgh, UK.; College of Medicine & Veterinary Medicine, University of Edinburgh, Edinburgh, UK. |
| Source: | BMC ophthalmology [BMC Ophthalmol] 2018 Jan 30; Vol. 18 (1), pp. 20. Date of Electronic Publication: 2018 Jan 30. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: BioMed Central Country of Publication: England NLM ID: 100967802 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2415 (Electronic) Linking ISSN: 14712415 NLM ISO Abbreviation: BMC Ophthalmol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
